我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
10
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1948
已完成
9
90.0%
招募中
1
10.0%
暂无批准数据
- Astria Therapeutics has granted exclusive development and commercialization rights for navenibart in Japan to Kaken Pharmaceutical in a deal worth up to $32 million. - Navenibart is a long-acting monoclonal antibody currently in Phase 3 trials designed for the preventative treatment of hereditary angioedema. - The partnership includes an upfront payment of $16 million, potential milestone payments of another $16 million, and tiered royalties up to 30 percent. - Kaken will support the ongoing ALPHA-ORBIT Phase 3 trial in Japan and manage regulatory submissions for commercialization.
